Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
David M Brown,David S Boyer,Diana V,Charles C Wykoff,Taiji Sakamoto,Peter Win,Sunir Joshi,Hani Salehi-Had,András Seres,Alyson J Berliner,Sergio Leal,Robert Vitti,Karen W Chu,Kimberly Reed,Rohini Rao,Yenchieh Cheng,Wei Sun,Delia Voronca,Rafia Bhore,Ursula Schmidt-Ott,Thomas Schmelter,Andrea Schulze,Xin Zhang,Boaz Hirshberg,George D Yancopoulos,Sobha Sivaprasad,PHOTON Investigators,Prema Abraham,Christopher Aderman,Kunihiko Akiyama,Daniel V. Alfaro,Fareed A. Ali,Payam Amini,Andres Emanuelli Anzalotta,György Bátor,Ivan Batlle,Adam Berger,Ramanath Bhandari,William Bridges,Christian Brinkmann,Jamin Brown,Stuart Burgess,Jorge Calzada,Antonio Capone,Dana Cervena,Steven Charles,Nauman Chaudhry,David Chow,W. Lloyd Clark,Paul Conrad,Matthew Cunningham,Hajir Dadgostar,Amr Dessouki,Dana Deupree,Christopher Devine,David Eichenbaum,Jan Ernest,Nicolas Feltgen,Moss Fenberg,Philip Ferrone,Ronald Frenkel,Scott Friedman,Julie Gasperini,Adam Gerstenblith,Ghassan Ghorayeb,Michel Giunta,Mitchell Goff,Liliya Golas,Joseph M. Googe,Jordana Goren Fein,Curtis Hagedorn,Akira Hagiwara,Paul Hahn,Richard Hairston,Jason Handza,Vivienne Hau,Ken Hayashi,Jeffrey Heier,Vrinda Hershberger,Patrick Higgins,Yoshio Hirano,Shigeru Honda,Yasuko Ikegami,Yuichiro Ishida,Isao Ishikawa,Kiyoshi Ishii,Eric P. Jablon,Atul Jain,Yuichi Kaji,Kapil Kapoor,Ágnes Kerényi,Kazuhiro Kimura,Genichiro Kishino,Katalin Kiss,Takashi Kitaoka,James M. Klancnik,Namie Kobayashi,Jiro Kogo,Vladimir Korda,Erik Kruger,Sentaro Kusuhara,Wilfredo Lara,Ketan Laud,Seong Lee,James Luu,Dennis Marcus,Calvin Mein,Annal Meleth,Tibor Milibák,Yoshinori Mitamura,Toshinori Murata,Sumiyo Noge,Hajime Onoe,James Osher,András Papp,Justin Parschauer,Sugat Patel,Sunil Patel,Matthew Pezda,Ashkan Pirouz,Pradeep Prasad,Omar Punjabi,Llewelyn Rao,Richard Roe,Ramin Schadlu,Eric Schneider,Ankur Shah,Milan Shah,Sandeep Shah,Sumit Shah,Ashish Sharma,Veeral Sheth,Masahiko Shimura,Lawrence Singerman,Georg Spital,Robert Stoltz,Eric Suan,Kiyoshi Suzuma,Hidenori Takahashi,Yoshihiro Takamura,Masaru Takeuchi,Jeffrey Tan,Benjamin Thomas,-Molnár Edit Tóth,Tetsuo Ueda,Hiroaki Ushida,Attila Vajas,Deepali Varma,Balázs Varsányi,Miroslav Veith,Pamela Weber,Raymond Wee,Geoff Williams,Haruhiko Yamada,Yoshihiro Yonekawa,Shigeo Yoshida,Diana V Do,Antonio Capone Jr.,Paul Conrad III,Joseph M. Googe Jr.,Edit Tóth,-Molnár
DOI: https://doi.org/10.1016/s0140-6736(23)02577-1
IF: 202.731
2024-03-01
The Lancet
Abstract:BACKGROUND: A high-dose formulation of intravitreal aflibercept (8 mg) could improve treatment outcomes in diabetic macular oedema (DMO) by requiring fewer injections than the standard comparator, aflibercept 2 mg. We report efficacy and safety results of aflibercept 8 mg versus 2 mg in patients with DMO.METHODS: PHOTON was a randomised, double-masked, non-inferiority, phase 2/3 trial performed at 138 hospitals and specialty retina clinics in seven countries. Eligible patients were adults aged 18 years or older with type 1 or 2 diabetes and centre-involved DMO. Patients were randomly assigned (1:2:1) to intravitreal aflibercept 2 mg every 8 weeks (2q8), aflibercept 8 mg every 12 weeks (8q12), or aflibercept 8 mg every 16 weeks (8q16), following initial monthly dosing. From week 16, dosing intervals for the aflibercept 8 mg groups were shortened if patients met prespecified dose regimen modification criteria denoting disease activity. The primary endpoint was change from baseline in best-corrected visual acuity (BCVA) at week 48 (non-inferiority margin of 4 letters). Efficacy and safety analyses included all randomly assigned patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov (NCT04429503).FINDINGS: Between June 29, 2020, and June 28, 2021, 970 patients were screened for eligibility. After exclusions, 660 patients were enrolled and randomly assigned to receive aflibercept 8q12 (n=329), 8q16 (n=164), or 2q8 (n=167); two patients were randomly assigned in error and did not receive treatment. 658 (99·7%) patients were treated and included in the full analysis set and safety analysis set (8q12 n=328, 8q16 n=163, and 2q8 n=167). Mean patient age was 62·3 years (SD 10·4). 401 (61%) patients were male. 471 (72%) patients were White. Aflibercept 8q12 and 8q16 demonstrated non-inferior BCVA gains to aflibercept 2q8 (BCVA mean change from baseline 8·8 letters [SD 9·0] in the 8q12 group, 7·9 letters [8·4] in the 8q16 group, and 9·2 letters [9·0] in the 2q8 group). The difference in least squares means was -0·57 letters (95% CI -2·26 to 1·13, p value for non-inferiority <0·0001) between 8q12 and 2q8 and -1·44 letters (-3·27 to 0·39, p value for non-inferiority 0·0031) between aflibercept 8q16 and 2q8. Proportions of patients with ocular adverse events in the study eye were similar across groups (8q12 n=104 [32%], 8q16 n=48 [29%], and 2q8 n=46 [28%]).INTERPRETATION: Aflibercept 8 mg demonstrated efficacy and safety with extended dosing intervals and could decrease treatment burden in patients with DMO.FUNDING: Regeneron Pharmaceuticals and Bayer.
medicine, general & internal